Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...
EUR/USD struggles to hold Thursday’s gains near the psychological level of 1.0500 as the US Dollar (USD) strives to gain ...
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...
MUNICH, Germany, and BASILDON, UK I February 13, 2025 I LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific ...
DIA's Europe Annual Meeting, featuring discussions from top European health leaders, will be held March 18-20 in Basel.
C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.
Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication options. Gilead is a major player in the HIV and AIDS resear ...
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir?the company's twice-yearly injectable HIV ...
Hyderabad: Aurobindo Pharma has announced that the European Commission (EC) has granted marketing authorization in the ...
Biologics Ltd (BBL), a subsidiary of Biocon Limited, has secured a major regulatory milestone with the European Commission ...